Investment Research Analysts’ Latest Ratings Updates for TearLab Corp (TEAR)

Investment Research Analysts’ Latest Ratings Updates for TearLab Corp (TEAR)

A number of firms have modified their ratings and price targets on shares of TearLab Corp (NASDAQ: TEAR) recently:

TearLab Corp (NASDAQ:TEAR) opened at 3.18 on Tuesday. TearLab Corp has a one year low of $2.95 and a one year high of $9.10. The firm’s 50 day moving average price is $5.05 and its 200-day moving average price is $5.79. The company’s market capitalization is $17.07 million.

TearLab Corp (NASDAQ:TEAR) last posted its earnings results on Thursday, March 9th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.09. The business had revenue of $7.12 million for the quarter, compared to analyst estimates of $7.71 million. The firm’s revenue was up 4.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.26) earnings per share. Equities analysts forecast that TearLab Corp will post ($2.62) earnings per share for the current fiscal year.

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.

Related posts

Leave a Comment